Options for prevention of respiratory tract infection

The article presents the results of studies showing prospective clinical and cost-effectiveness of vaccination for pneumococcal conjugate vaccine (PCV) Prevenar® 13 patients with lung disease for 2 years.Material and Methods: The study included a total of 115 male patients treated in Regional Clinical Hospital №4 pulmonology and urban center of the city of Chelyabinsk in 2012-2014. The average age of study patients was 62.09±9.22 years. All persons had a comprehensive clinical and instrumental examination. The degree of dyspnea was evaluated on the scale of the Medical Research Centre (Medical Research Consil Scale - MRC). Estimated was the frequency of hospitalization with acute exacerbations of chronic obstructive pulmonary disease (COPD), the number of pneumonia in 2 years. 13-valent PCV (PKV13) Prevenar® 13 was used for vaccination.Results and conclusions: the vaccinated patients with comorbidity had significant reduction in exacerbations of COPD 8 times and thereby reducing the number of admissions to 4 times in 2 years. The use of the vaccine PKV13 to minimize the costs of the health care system for the treatment of patients with COPD. This saves up to 64% of the budget year after vaccination and in 1.5 years - to 73.6%. At the same time the use of 23-valent pneumococcal polysaccharide vaccine was associated with a reduction in clinical efficacy over time, and the possible budget savings amounted to 55 and 47% next year andyears, respectively.

chronic obstructive pulmonary disease, vaccination